These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 12647312

  • 21. Voyages to the (un)known: adaptive design of bioactive compounds.
    Schneider G, Hartenfeller M, Reutlinger M, Tanrikulu Y, Proschak E, Schneider P.
    Trends Biotechnol; 2009 Jan; 27(1):18-26. PubMed ID: 19004513
    [Abstract] [Full Text] [Related]

  • 22. High-throughput characterization and quality control of small-molecule combinatorial libraries.
    Kenseth JR, Coldiron SJ.
    Curr Opin Chem Biol; 2004 Aug; 8(4):418-23. PubMed ID: 15288253
    [Abstract] [Full Text] [Related]

  • 23. Mass spectrometric techniques for label-free high-throughput screening in drug discovery.
    Roddy TP, Horvath CR, Stout SJ, Kenney KL, Ho PI, Zhang JH, Vickers C, Kaushik V, Hubbard B, Wang YK.
    Anal Chem; 2007 Nov 01; 79(21):8207-13. PubMed ID: 17902631
    [Abstract] [Full Text] [Related]

  • 24. Process technologies for purity enhancement of large discovery libraries.
    Pottorf RS, Player MR.
    Curr Opin Drug Discov Devel; 2004 Nov 01; 7(6):777-83. PubMed ID: 15595438
    [Abstract] [Full Text] [Related]

  • 25. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 01; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 26. Drug discovery using support vector machines. The case studies of drug-likeness, agrochemical-likeness, and enzyme inhibition predictions.
    Zernov VV, Balakin KV, Ivaschenko AA, Savchuk NP, Pletnev IV.
    J Chem Inf Comput Sci; 2003 Dec 01; 43(6):2048-56. PubMed ID: 14632457
    [Abstract] [Full Text] [Related]

  • 27. The evolution of microarrayed compound screening.
    Hoever M, Zbinden P.
    Drug Discov Today; 2004 Apr 15; 9(8):358-65. PubMed ID: 15081963
    [Abstract] [Full Text] [Related]

  • 28. Virtual screening - what does it give us?
    Köppen H.
    Curr Opin Drug Discov Devel; 2009 May 15; 12(3):397-407. PubMed ID: 19396741
    [Abstract] [Full Text] [Related]

  • 29. Designing screens: how to make your hits a hit.
    Walters WP, Namchuk M.
    Nat Rev Drug Discov; 2003 Apr 15; 2(4):259-66. PubMed ID: 12669025
    [Abstract] [Full Text] [Related]

  • 30. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
    Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, Hamon J, Urban L, Whitebread S, Jenkins JL.
    ChemMedChem; 2007 Jun 15; 2(6):861-73. PubMed ID: 17477341
    [Abstract] [Full Text] [Related]

  • 31. A review of high throughput technology for the screening of natural products.
    Mishra KP, Ganju L, Sairam M, Banerjee PK, Sawhney RC.
    Biomed Pharmacother; 2008 Feb 15; 62(2):94-8. PubMed ID: 17692498
    [Abstract] [Full Text] [Related]

  • 32. Fragment-based activity space: smaller is better.
    Hesterkamp T, Whittaker M.
    Curr Opin Chem Biol; 2008 Jun 15; 12(3):260-8. PubMed ID: 18316043
    [Abstract] [Full Text] [Related]

  • 33. Prediction of aqueous solubility of a diverse set of compounds using quantitative structure-property relationships.
    Cheng A, Merz KM.
    J Med Chem; 2003 Aug 14; 46(17):3572-80. PubMed ID: 12904062
    [Abstract] [Full Text] [Related]

  • 34. Affinity-based screening techniques for enhancing lead discovery.
    Comess KM, Schurdak ME.
    Curr Opin Drug Discov Devel; 2004 Jul 14; 7(4):411-6. PubMed ID: 15338950
    [Abstract] [Full Text] [Related]

  • 35. Predicting antitrichomonal activity: a computational screening using atom-based bilinear indices and experimental proofs.
    Marrero-Ponce Y, Meneses-Marcel A, Castillo-Garit JA, Machado-Tugores Y, Escario JA, Barrio AG, Pereira DM, Nogal-Ruiz JJ, Arán VJ, Martínez-Fernández AR, Torrens F, Rotondo R, Ibarra-Velarde F, Alvarado YJ.
    Bioorg Med Chem; 2006 Oct 01; 14(19):6502-24. PubMed ID: 16875830
    [Abstract] [Full Text] [Related]

  • 36. Natural product hybrids as new leads for drug discovery.
    Tietze LF, Bell HP, Chandrasekhar S.
    Angew Chem Int Ed Engl; 2003 Sep 05; 42(34):3996-4028. PubMed ID: 12973759
    [Abstract] [Full Text] [Related]

  • 37. Lead-oriented synthesis: a new opportunity for synthetic chemistry.
    Nadin A, Hattotuwagama C, Churcher I.
    Angew Chem Int Ed Engl; 2012 Jan 27; 51(5):1114-22. PubMed ID: 22271624
    [Abstract] [Full Text] [Related]

  • 38. Hit discovery and hit-to-lead approaches.
    Keseru GM, Makara GM.
    Drug Discov Today; 2006 Aug 27; 11(15-16):741-8. PubMed ID: 16846802
    [Abstract] [Full Text] [Related]

  • 39. Which aspects of HTS are empirically correlated with downstream success?
    Bender A, Bojanic D, Davies JW, Crisman TJ, Mikhailov D, Scheiber J, Jenkins JL, Deng Z, Hill WA, Popov M, Jacoby E, Glick M.
    Curr Opin Drug Discov Devel; 2008 May 27; 11(3):327-37. PubMed ID: 18428086
    [Abstract] [Full Text] [Related]

  • 40. Guiding molecules towards drug-likeness.
    Egan WJ, Walters WP, Murcko MA.
    Curr Opin Drug Discov Devel; 2002 Jul 27; 5(4):540-9. PubMed ID: 12197312
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.